Houdini Bio is a deep tech biotechnology company providing the critical enabling infrastructure for next-generation genetic medicines. By combining machine learning with a mechanistic understanding of cellular silencing pathways, Houdini Bio's DNA rewiring toolkit allows therapy developers to maximise transgene expression, durability and scalably. Headquartered in London, Houdini Bio is unchaining the full potential of genetic medicine to make tomorrow's curative therapies more commercially viable, effective and clinically safe.
Houdini Bio: Venture Capital Funding History
Houdini Bio
Houdini Bio
- Life Sciences
- London, United Kingdom
- £1.5m
- houdinibio.com
- Update Information
More venture news
- 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences - 15 Oct 2026

MedcotecMedcotec announces its £2.4m seed round from VCs to help pharma manufacturers transfer powders with single-use valves
SeedLife Sciences - 15 Oct 2026

Silvia BioSilvia Bio raises a £3m seed round led by Northern Gritstone to improve complex biopharmaceutical manufacturing
SeedLife Sciences
